TeloAT2

About Rejuvenation Technologies

Rejuvenation Technologies is an early-stage biotech developing a novel therapeutic approach to target biological aging at its chromosomal source. Its core technology utilizes transient telomerase activation via modified mRNA delivered by proprietary lipid nanoparticles, aiming to safely reverse telomere shortening in specific tissues. The company is preparing to initiate its first clinical trials in Australia for pulmonary fibrosis, chronic liver disease, and a hematologic indication, leveraging accelerated regulatory pathways. With a seasoned leadership team and over $8M in grant funding secured since its founding, Rejuvenation is positioning itself at the forefront of the longevity and regenerative medicine space.

Therapeutic Areas

Other Pulmonary Fibrosis Drugs